Tweet
Posted 7 months, 2 weeks ago (0 comments)
Horizon Therapeutics has announced a short-term supply disruption for TEPEZZA (TM), a medication approved earlier this year for the treatment of thyroid eye disease.
UPDATE (Feb. 4th): Horizon Therapeutics has released a new FAQ regarding the supply disruption. Please note that this information is being provided as a service to our patient and physician community, and that specific questions should be directed to Horizon Patient Services at the number included in the FAQ.
Comments
You must log in to comment.